MCID: BSL007
MIFTS: 66

Basal Cell Carcinoma

Categories: Rare diseases, Respiratory diseases, Genetic diseases, Cancer diseases, Skin diseases

Aliases & Classifications for Basal Cell Carcinoma

MalaCards integrated aliases for Basal Cell Carcinoma:

Name: Basal Cell Carcinoma 12 72 36 28 14 69
Basal Cell Cancer 12 51 69
Malignant Basal Cell Tumor 12 69
Basal Cell Neoplasm 12 69
Experimental Organism Basal Cell Carcinoma 69
Nodulo-Ulcerative Basal Cell Carcinoma 69
Malignant Basal Cell Neoplasm 12
Basal Cell Carcinoma of Skin 12
Basal Cell Carcinoma Nos 12
Basal Cell Neoplasm Nos 12
Epithelioma Basal Cell 12
Carcinoma, Basal Cell 41
Neoplasms, Basal Cell 41
Carcinoma Basal Cell 51
Basal Cell Tumor 12
Rodent Ulcer 12

Classifications:



Summaries for Basal Cell Carcinoma

Disease Ontology : 12 A skin carcinoma affecting basal cells.

MalaCards based summary : Basal Cell Carcinoma, also known as basal cell cancer, is related to basal cell carcinoma, multiple and basal cell carcinoma 1. An important gene associated with Basal Cell Carcinoma is SMO (Smoothened, Frizzled Class Receptor), and among its related pathways/superpathways are Basal cell carcinoma and G-Beta Gamma Signaling. The drugs Erivedge and Intron A have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and brain, and related phenotypes are cellular and digestive/alimentary

Wikipedia : 72 Basal-cell carcinoma (BCC), also known as basal-cell cancer, is the most common type of skin cancer. It... more...

Related Diseases for Basal Cell Carcinoma

Diseases in the Small Cell Carcinoma family:

Basal Cell Carcinoma 1 Basal Cell Carcinoma 2
Basal Cell Carcinoma 3 Basal Cell Carcinoma 4
Basal Cell Carcinoma 5 Basal Cell Carcinoma 6
Basal Cell Carcinoma 7 Cell Type Cancer
Cell Type Benign Neoplasm Basal Cell Carcinoma
Large Cell Carcinoma Basal Cell Carcinoma, Multiple

Diseases related to Basal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 309)
# Related Disease Score Top Affiliating Genes
1 basal cell carcinoma, multiple 34.6 PTCH1 PTCH2 SMO
2 basal cell carcinoma 1 34.6 BCC1 PALB2 PTCH1 SMO
3 nodular basal cell carcinoma 34.5 KRT15 KRT17 PTCH1
4 basal cell carcinoma, infundibulocystic 34.4 KRT17 SUFU
5 basal cell nevus syndrome 34.3 GLI1 GLI2 PTCH1 PTCH2 SHH SMO
6 morpheaform basal cell carcinoma 34.0 KRT15 KRT17
7 actinic keratosis 31.6 KRT17 MC1R TP53
8 keratocystic odontogenic tumor 31.2 GLI1 PTCH1 SHH SMO SUFU TP53
9 medulloblastoma 31.2 CTNNB1 GLI1 PTCH1 PTCH2 SHH SMO
10 ameloblastoma 31.0 GLI1 PTCH1 SMO
11 childhood medulloblastoma 30.5 GLI2 PTCH1 SUFU
12 spiradenoma 30.4 CYLD KRT15 TP53
13 basal cell carcinoma 7 12.3
14 superficial basal cell carcinoma 12.3
15 pigmented basal cell carcinoma 12.3
16 adenoid basal cell carcinoma 12.2
17 clear cell basal cell carcinoma 12.2
18 sarcomatoid basal cell carcinoma 12.2
19 vulva basal cell carcinoma 12.2
20 vulvar basal cell carcinoma 12.2
21 infiltrative basal cell carcinoma 12.2
22 cystic basal cell carcinoma 12.2
23 metatypical basal cell carcinoma 12.2
24 scrotum basal cell carcinoma 12.2
25 micronodular basal cell carcinoma 12.2
26 penis basal cell carcinoma 12.2
27 fibroepithelial basal cell carcinoma 12.2
28 bazex syndrome 12.1
29 basal cell carcinoma 2 12.1
30 basal cell carcinoma 3 12.1
31 basal cell carcinoma 4 12.1
32 basal cell carcinoma 5 12.1
33 basal cell carcinoma 6 12.1
34 anal margin basal cell carcinoma 12.1
35 external ear basal cell carcinoma 12.1
36 follicular basal cell carcinoma 12.1
37 signet ring basal cell carcinoma 12.1
38 sebaceous basal cell carcinoma 12.0
39 rombo syndrome 11.9
40 brooke-spiegler syndrome 11.3
41 multiple familial trichoepithelioma 11.3
42 xeroderma pigmentosum, complementation group a 11.3
43 xeroderma pigmentosum, complementation group c 11.3
44 adamantinoid basal cell epithelioma 11.1
45 trichoepithelioma, multiple familial, 1 11.1
46 eosinophilic granuloma 11.0
47 prostate cancer 10.9
48 xeroderma pigmentosum, complementation group e 10.9
49 xeroderma pigmentosum, complementation group f 10.9
50 xeroderma pigmentosum, complementation group g 10.9

Graphical network of the top 20 diseases related to Basal Cell Carcinoma:



Diseases related to Basal Cell Carcinoma

Symptoms & Phenotypes for Basal Cell Carcinoma

MGI Mouse Phenotypes related to Basal Cell Carcinoma:

43 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.26 CTNNB1 CYLD GLI1 GLI2 KRT17 MC1R
2 digestive/alimentary MP:0005381 10.24 CTNNB1 CYLD GLI1 GLI2 KRT17 PTCH1
3 growth/size/body region MP:0005378 10.23 SMO SUFU TP53 CTNNB1 CYLD GLI1
4 craniofacial MP:0005382 10.21 GLI1 GLI2 KRT17 MC1R PTCH1 SHH
5 integument MP:0010771 10.14 CTNNB1 CYLD GLI2 KRT17 MC1R PALB2
6 embryo MP:0005380 10.13 CTNNB1 GLI1 GLI2 PALB2 PTCH1 SHH
7 limbs/digits/tail MP:0005371 10.11 PALB2 PTCH1 SHH SMO SUFU TP53
8 neoplasm MP:0002006 10.02 CTNNB1 CYLD GLI1 MC1R PALB2 PTCH1
9 hearing/vestibular/ear MP:0005377 9.98 PTCH1 SHH SMO TP53 CTNNB1 GLI2
10 no phenotypic analysis MP:0003012 9.91 CTNNB1 GLI1 GLI2 TP53 KRT17 MC1R
11 normal MP:0002873 9.85 CTNNB1 CYLD GLI1 GLI2 PTCH1 PTCH2
12 pigmentation MP:0001186 9.43 CTNNB1 KRT17 MC1R PTCH1 SUFU TP53
13 respiratory system MP:0005388 9.28 CTNNB1 CYLD GLI1 GLI2 PTCH1 SHH

Drugs & Therapeutics for Basal Cell Carcinoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Erivedge 17 45 VISMODEGIB Genentech January 2012
2
Intron A 17 45 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
3
Odomzo 17 45 SONIDEGIB PHOSPHATE Novartis Jul-15

Drugs for Basal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 252)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 106-60-5 137
2
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 99011-02-6 57469
3
Everolimus Approved Phase 4,Phase 1 159351-69-6 6442177
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 22916-47-8 4189
5
Sirolimus Approved, Investigational Phase 4,Phase 1 53123-88-9 46835353 6436030 5284616
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
7 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
8 Methyl 5-aminolevulinate Phase 4,Phase 3,Phase 2,Phase 1
9 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
10 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1
11 Interferon Inducers Phase 4,Phase 3,Phase 2,Phase 1
12 interferons Phase 4,Phase 3,Phase 2,Phase 1
13 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Antiviral Agents Phase 4,Phase 2,Phase 1
15 Anti-Bacterial Agents Phase 4,Phase 1,Phase 2
16 Antibiotics, Antitubercular Phase 4,Phase 1,Phase 2
17 Antirheumatic Agents Phase 4,Phase 2
18 Immunosuppressive Agents Phase 4,Phase 2,Phase 1
19 Interferon-alpha Phase 4
20 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
21 Calcineurin Inhibitors Phase 4
22 Cyclosporins Phase 4
23
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
24
Zinc Approved, Investigational Phase 3 7440-66-6 32051 23994
25
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
26
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
27
Cevimeline Approved Phase 3 107233-08-9 25137844 83898
28
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
29
Doxepin Approved, Investigational Phase 3 1668-19-5 667468 667477
30
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
31
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
32
Verteporfin Approved, Investigational Phase 3 129497-78-5
33
Ornithine Approved, Nutraceutical Phase 3,Phase 2 70-26-8, 3184-13-2 6262
34
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1,Phase 2 302-79-4 5538
35
B-Carotene Approved, Nutraceutical Phase 3 7235-40-7 5280489
36 Tocopherol Approved, Investigational, Nutraceutical Phase 3
37
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 54670067 5785
38
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
39 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
40
Docetaxel Approved May 1996, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124 9877265
41 Anesthetics Phase 3,Early Phase 1
42 Liver Extracts Phase 3,Phase 2,Phase 1
43 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3,Early Phase 1
44 Antiparasitic Agents Phase 3,Phase 2,Phase 1
45 Antiprotozoal Agents Phase 3,Phase 2,Phase 1
46 Keratolytic Agents Phase 3,Phase 2
47 Antioxidants Phase 3
48 Carotenoids Phase 3
49 Micronutrients Phase 3,Phase 2,Phase 1
50 Protective Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 284)

# Name Status NCT ID Phase Drugs
1 Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate Unknown status NCT01491711 Phase 4 Methylaminolevulinate PDT in 2 sessions;Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
2 Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma Unknown status NCT00803907 Phase 4 Imiquimod 5% cream
3 Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage Completed NCT00314756 Phase 4 imiquimod
4 Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC) Completed NCT00581425 Phase 4
5 Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma Completed NCT00204555 Phase 4 Imiquimod
6 Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients Completed NCT00129961 Phase 4 sirolimus;cyclosporine or tacrolimus
7 VISmodegib for ORbital and Periocular Basal Cell Carcinoma Recruiting NCT02436408 Phase 4 Vismodegib
8 Periocular Basal Cell Carcinoma (BCC): Permanent vs. Frozen Section Pathological Control Unknown status NCT00663650 Phase 3
9 Treatment of Primary Basal Cell Carcinomas of the Skin With Combination of Topical Imiquimod and Cryosurgery Completed NCT01212562 Phase 3
10 Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream Completed NCT00189306 Phase 3 Imiquimod 5% cream
11 A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma Completed NCT00189241 Phase 3 imiquimod
12 Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Cell Carcinoma Completed NCT00472108 Phase 3
13 Metvix PDT Versus Cryotherapy in Patients With Primary Superficial Basal Cell Carcinoma Completed NCT00469417 Phase 3
14 A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence Completed NCT00129519 Phase 3 Imiquimod 5% cream
15 Comparison of Two Schemes of Cryosurgery and Imiquimod Combination Treatment for Basal Cell Carcinoma Completed NCT01212549 Phase 3
16 Metvix PDT in Patients With "High Risk" Basal Cell Carcinoma Completed NCT00473343 Phase 3
17 Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer Completed NCT00066872 Phase 3 imiquimod
18 PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Call Carcinoma Completed NCT00472043 Phase 3
19 Fractional CO2 Laser Assisted Photodynamic Therapy Completed NCT01260987 Phase 2, Phase 3 Conventional photodynamic therapy;Fractional CO2 laser assisted PDT
20 Topical Green Tea Ointment in Treatment of Superficial Skin Cancer Completed NCT02029352 Phase 2, Phase 3 Sinecatechins 10%;Placebo
21 Aldara for the Treatment of Large and/or Multiple sBCC Completed NCT00189280 Phase 3 Imiquimod
22 Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer Completed NCT00005884 Phase 3 eflornithine
23 Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer Completed NCT00007631 Phase 3 Tretinoin 0.1% cream or placebo
24 Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals. Completed NCT00272428 Phase 3
25 PDT With Metvix® 160 mg/g Cream in Organ Transplant Recipients With Non-melanoma Skin Cancer Completed NCT00472459 Phase 3
26 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
27 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
28 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
29 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
30 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
31 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
32 Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Completed NCT01362140 Phase 3 Darbepoetin alfa;Placebo
33 Radiotherapy or Imiquimod in Complex Lentigo Maligna Recruiting NCT02394132 Phase 3 Imiquimod
34 Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma Active, not recruiting NCT02242929 Phase 3 Imiquimod 5% cream with prior curettage
35 Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy Active, not recruiting NCT02144077 Phase 3 BF-200 ALA;methyl-aminolevulinate
36 Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin. Terminated NCT00049959 Phase 3 verteporfin PDT
37 Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ Transplanted Patients Terminated NCT01532453 Phase 3
38 Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) Withdrawn NCT03070691 Phase 2, Phase 3 LDE225B;Vehicle
39 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
40 Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight Unknown status NCT01349361 Phase 2
41 Safety and Efficacy of Oshadi D and Oshadi R in Basal Cell Carcinoma Patients Prior to Tumor Excision a Phase 2 Study Unknown status NCT02007317 Phase 2 Oshadi D & Oshadi R
42 Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Skin Cancer Unknown status NCT00747903 Phase 2 aminolevulinic acid hydrochloride
43 Early Detection of Skin Cancer With Sensor Technology Unknown status NCT02668614 Phase 2
44 Low Fat Diet to Prevent Disease Progression in Patients With Skin Cancer Unknown status NCT00003097 Phase 2
45 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
46 Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas Completed NCT02828111 Phase 2 patidegib gel 2% - cohort 1;patidegib gel 4% - cohort 2;Vehicle - cohort 1;patidegib gel 2% - cohort 3;patidegib gel 4% - cohort 4;vehicle - cohort 2;Vehicle - cohort 3;Vehicle - cohort 4
47 A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas Completed NCT01815840 Phase 2 Vismodegib;Placebo
48 Vismodegib for Treatment of Basal Cell Carcinoma Completed NCT01543581 Phase 2 Vismodegib;Placebo
49 Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma Completed NCT00108121 Phase 2 PEP005
50 Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas Completed NCT01108094 Phase 2 Itraconazole

Search NIH Clinical Center for Basal Cell Carcinoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: carcinoma, basal cell

Genetic Tests for Basal Cell Carcinoma

Genetic tests related to Basal Cell Carcinoma:

# Genetic test Affiliating Genes
1 Basal Cell Carcinoma 28

Anatomical Context for Basal Cell Carcinoma

MalaCards organs/tissues related to Basal Cell Carcinoma:

38
Skin, Lung, Brain, Kidney, Liver, Breast, Bone

Publications for Basal Cell Carcinoma

Articles related to Basal Cell Carcinoma:

(show top 50) (show all 1840)
# Title Authors Year
1
Erythrocyte Membrane Unsaturated (Mono and Poly) Fatty Acids Profile in Newly Diagnosed Basal Cell Carcinoma Patients. ( 29423386 )
2018
2
Features Causing Confusion between Basal Cell Carcinoma and Squamous Cell Carcinoma in Clinical Diagnosis. ( 29386834 )
2018
3
PTCH1 Germline Mutations and the Basaloid Follicular Hamartoma Values in the Tumor Spectrum of Basal Cell Carcinoma Syndrome (NBCCS). ( 29277811 )
2018
4
Optical coherence tomography image processing for in vivo 3-dimensional visualization of basal cell carcinoma. ( 29368446 )
2018
5
Correction to:A Cancer associated fibroblasts (CAFs) are activated in cutaneous basal cell carcinoma and in the peritumoural skin. ( 29382305 )
2018
6
Tumor Architecture and Notch Signaling Modulate Drug Response in Basal Cell Carcinoma. ( 29395868 )
2018
7
An expanded study of long-pulsed 1064a88nm Nd:YAG laser treatment of basal cell carcinoma. ( 29436720 )
2018
8
Basal cell carcinoma of the scrotum: an important but easily overlooked entity. ( 29377295 )
2018
9
A randomized, multi-national, non-inferiority, phase III trial to evaluate the safety and efficacy of BF-200 ALA gel versus MAL cream in the treatment of non-aggressive basal cell carcinoma with photodynamic therapy (PDT). ( 29432644 )
2018
10
Dermoscopic and reflectance confocal microscopy features of two cases of vulvar basal cell carcinoma. ( 29445582 )
2018
11
Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies. ( 29399405 )
2018
12
Plaque-Type Syringoma Coexisting With Basal Cell Carcinoma. ( 29419541 )
2018
13
9q22.3 Microdeletion Syndrome with Multiple Basal Cell Carcinomas Treated with Vismodegib: Three Key Messages in One Patient. ( 29057423 )
2018
14
Angiosarcoma following treatment of basal cell carcinoma: a report of two cases. ( 29345300 )
2018
15
Intracranial regression of an advanced basal cell carcinoma using sonidegib and itraconazole after failure with vismodegib. ( 29387745 )
2018
16
Application of in vivo reflectance confocal microscopy (RCM) and ex vivo fluorescence confocal microscopy (FCM) in most common subtypes of Basal Cell Carcinoma and correlation with histopathology. ( 29405259 )
2018
17
Novel PTCH1 Gene Mutation in Nevoid Basal Cell Carcinoma Syndrome. ( 29381605 )
2018
18
Comparing Topical Treatments forA Basal Cell Carcinoma. ( 29395168 )
2018
19
Molecular Variations in Histologic Subtypes of Basal Cell Carcinoma. ( 28859735 )
2017
20
Risks of different skin tumor combinations after a first melanoma, squamous cell carcinoma and basal cell carcinoma in Dutch population based cohorts: 1989 - 2009. ( 28898461 )
2017
21
Vulvar basal cell carcinoma with adhesion of the labia majora and minora. ( 27917514 )
2017
22
A rare dermoscopic pattern of nodular basal cell carcinoma with amyloid deposition. ( 28087032 )
2017
23
Nevoid basal cell carcinoma syndrome caused by splicing mutations in the PTCH1 gene. ( 27561271 )
2017
24
Variation in dermoscopic features of basal cell carcinoma as a function of anatomic location and pigmentation status. ( 28886224 )
2017
25
Use of a cotton-tipped applicator for superior clinical diagnosis and biopsy of suspected basal cell carcinoma of the nasal ala. ( 27986150 )
2017
26
Multiple Basal Cell Carcinomas in a Patient of Oculocutaneous Albinism. ( 28405556 )
2017
27
FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma. ( 28073840 )
2017
28
Simultaneous Development of Three Different Neoplasms of Trichilemmoma, Desmoplastic Trichilemmoma and Basal Cell Carcinoma Arising from Nevus Sebaceus. ( 28913303 )
2017
29
Dynamic Thiol/Disulphide Homeostasis in patients with Basal Cell Carcinoma. ( 28067074 )
2017
30
Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5-aminolevulinic acid 20% versus two stage topical methylaminolevulinic acid: results of a randomized controlled trial. ( 28886209 )
2017
31
Basal Cell Carcinoma in Erythropoietic Protoporphyria: All About Ultraviolet Light? ( 28903600 )
2017
32
The concerted action of type 2 and type 3 deiodinases regulates the cell cycle and survival of basal cell carcinoma cells. ( 28088877 )
2017
33
Evaluation of the Level of Zinc and Malondialdehyde in Basal Cell Carcinoma. ( 28894712 )
2017
34
Photodynamic Therapy Effective for the Treatment of Actinic Keratosis and Basal Cell Carcinoma in Bullous Pemphigoid Patients. ( 28373119 )
2017
35
Emerging trends in the treatment of advanced basal cell carcinoma. ( 29407368 )
2017
36
Vulvar Basal Cell Carcinoma: Four Case Reports With Immunohistochemical Study. ( 28565920 )
2017
37
Reactive Eccrine Syringofibroadenoma Associated With Basal Cell Carcinoma: A Histologic Mimicker of Fibroepithelioma of Pinkus. ( 28902033 )
2017
38
Ambulatory Photodynamic Therapy for Superficial Basal Cell Carcinoma: An Effective Light Source? ( 28093601 )
2017
39
Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin. ( 28887802 )
2017
40
Complex functional and epithetic rehabilitation after ablation of recurrent retroauricular basal cell carcinoma - a case study. ( 29423354 )
2017
41
Photodynamic therapy with epidermal ablation using fractional CO2 laser for treating superficial basal cell carcinoma: A case series. ( 28647617 )
2017
42
Pulmonary metastases in a patient with an aggressive infiltrative basal cell carcinoma of the scalp. ( 28251897 )
2017
43
Peripheral Ameloblastoma: A Study of 18 Cases and Usage of Ber-EP4 Immunohistochemistry to Rule out a Diagnosis of Intraoral Basal Cell Carcinoma. ( 29247621 )
2017
44
Expression of oncogenic miR-17-92 and tumor suppressive miR-143-145 clusters in basal cell carcinoma and cutaneous squamous cell carcinoma. ( 28187958 )
2017
45
Polyalkylimide and Invasive Growth of Basal Cell Carcinoma of the Skin. ( 28857938 )
2017
46
Superficial basal cell carcinoma: A comparison of superficial only subtype with superficial combined with other subtypes by age, sex and anatomic site in 3150 cases. ( 28493477 )
2017
47
Long-Term Efficacy and Safety of Sonidegib in Patients With Locally Advanced and Metastatic Basal Cell Carcinoma: 30-Month Analysis of the Randomized Phase 2 BOLT Study. ( 28846163 )
2017
48
Microbiopsy Biomarker Profiling in a Superficial Melanoma Resembling a Pigmented Basal Cell Carcinoma. ( 28196220 )
2017
49
Five-Year Results of a Randomized Controlled Trial Comparing Effectiveness of Photodynamic Therapy, Topical Imiquimod, and Topical 5-Fluorouracil in Patients with Superficial Basal Cell Carcinoma. ( 29045820 )
2017
50
Pediatric nevoid basal cell carcinoma syndrome. ( 29360891 )
2017

Variations for Basal Cell Carcinoma

ClinVar genetic disease variations for Basal Cell Carcinoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PALB2 NM_024675.3(PALB2): c.1451T> A (p.Leu484Ter) single nucleotide variant Pathogenic rs786203714 GRCh38 Chromosome 16, 23635095: 23635095
2 SMO NM_005631.4(SMO): c.1417G> C (p.Asp473His) single nucleotide variant Pathogenic rs17710891 GRCh37 Chromosome 7, 128849189: 128849189

Cosmic variations for Basal Cell Carcinoma:

9 (show top 50) (show all 225)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM43635 TP53 skin,NS,carcinoma,basal cell carcinoma c.536A>T p.H179L 22
2 COSM44097 TP53 skin,NS,carcinoma,basal cell carcinoma c.530C>T p.P177L 22
3 COSM43920 TP53 skin,NS,carcinoma,basal cell carcinoma c.680C>T p.S227F 22
4 COSM43582 TP53 skin,NS,carcinoma,basal cell carcinoma c.454C>T p.P152S 22
5 COSM10812 TP53 skin,NS,carcinoma,basal cell carcinoma c.722C>T p.S241F 22
6 COSM45734 TP53 skin,NS,carcinoma,basal cell carcinoma c.622G>T p.D208Y 22
7 COSM44096 TP53 skin,NS,carcinoma,basal cell carcinoma c.748C>G p.P250A 22
8 COSM43616 TP53 skin,NS,carcinoma,basal cell carcinoma c.704A>G p.N235S 22
9 COSM43596 TP53 skin,NS,carcinoma,basal cell carcinoma c.841G>A p.D281N 22
10 COSM10656 TP53 skin,NS,carcinoma,basal cell carcinoma c.742C>T p.R248W 22
11 COSM44310 TP53 skin,NS,carcinoma,basal cell carcinoma c.738G>A p.M246I 22
12 COSM11084 TP53 skin,NS,carcinoma,basal cell carcinoma c.517G>A p.V173M 22
13 COSM45138 TP53 skin,NS,carcinoma,basal cell carcinoma c.853G>C p.E285Q 22
14 COSM43700 TP53 skin,NS,carcinoma,basal cell carcinoma c.712T>A p.C238S 22
15 COSM10768 TP53 skin,NS,carcinoma,basal cell carcinoma c.535C>T p.H179Y 22
16 COSM10887 TP53 skin,NS,carcinoma,basal cell carcinoma c.833C>G p.P278R 22
17 COSM44241 TP53 skin,NS,carcinoma,basal cell carcinoma c.592G>T p.E198* 22
18 COSM10660 TP53 skin,NS,carcinoma,basal cell carcinoma c.818G>A p.R273H 22
19 COSM45751 TP53 skin,NS,carcinoma,basal cell carcinoma c.511G>C p.E171Q 22
20 COSM44130 TP53 skin,NS,carcinoma,basal cell carcinoma c.477C>T p.A159A 22
21 COSM10705 TP53 skin,NS,carcinoma,basal cell carcinoma c.586C>T p.R196* 22
22 COSM10728 TP53 skin,NS,carcinoma,basal cell carcinoma c.839G>A p.R280K 22
23 COSM43842 TP53 skin,NS,carcinoma,basal cell carcinoma c.770T>C p.L257P 22
24 COSM43695 TP53 skin,NS,carcinoma,basal cell carcinoma c.748C>T p.P250S 22
25 COSM11376 TP53 skin,NS,carcinoma,basal cell carcinoma c.737T>G p.M246R 22
26 COSM10704 TP53 skin,NS,carcinoma,basal cell carcinoma c.844C>T p.R282W 22
27 COSM10939 TP53 skin,NS,carcinoma,basal cell carcinoma c.832C>T p.P278S 22
28 COSM10662 TP53 skin,NS,carcinoma,basal cell carcinoma c.743G>A p.R248Q 22
29 COSM45074 TP53 skin,NS,carcinoma,basal cell carcinoma c.829T>G p.C277G 22
30 COSM10863 TP53 skin,NS,carcinoma,basal cell carcinoma c.833C>T p.P278L 22
31 COSM45739 TP53 skin,NS,carcinoma,basal cell carcinoma c.677G>C p.G226A 22
32 COSM45322 TP53 skin,NS,carcinoma,basal cell carcinoma c.757A>G p.T253A 22
33 COSM44606 TP53 skin,NS,carcinoma,basal cell carcinoma c.665C>T p.P222L 22
34 COSM44295 TP53 skin,NS,carcinoma,basal cell carcinoma c.993+1G>A p.? 22
35 COSM10650 TP53 skin,NS,carcinoma,basal cell carcinoma c.529C>T p.P177S 22
36 COSM43665 TP53 skin,NS,carcinoma,basal cell carcinoma c.746G>C p.R249T 22
37 COSM45774 TP53 skin,NS,carcinoma,basal cell carcinoma c.899C>G p.P300R 22
38 COSM10749 TP53 skin,NS,carcinoma,basal cell carcinoma c.830G>T p.C277F 22
39 COSM11449 TP53 skin,NS,carcinoma,basal cell carcinoma c.388C>T p.L130F 22
40 COSM10771 TP53 skin,NS,carcinoma,basal cell carcinoma c.749C>T p.P250L 22
41 COSM44068 TP53 skin,NS,carcinoma,basal cell carcinoma c.532C>A p.H178N 22
42 COSM11152 TP53 skin,NS,carcinoma,basal cell carcinoma c.700T>C p.Y234H 22
43 COSM45834 TP53 skin,NS,carcinoma,basal cell carcinoma c.409C>A p.L137M 22
44 COSM10905 TP53 skin,NS,carcinoma,basal cell carcinoma c.451C>T p.P151S 22
45 COSM10654 TP53 skin,NS,carcinoma,basal cell carcinoma c.637C>T p.R213* 22
46 COSM6932 TP53 skin,NS,carcinoma,basal cell carcinoma c.733G>A p.G245S 22
47 COSM45424 TP53 skin,NS,carcinoma,basal cell carcinoma c.781A>T p.S261C 22
48 COSM10659 TP53 skin,NS,carcinoma,basal cell carcinoma c.817C>T p.R273C 22
49 COSM10794 TP53 skin,NS,carcinoma,basal cell carcinoma c.796G>A p.G266R 22
50 COSM10648 TP53 skin,NS,carcinoma,basal cell carcinoma c.524G>A p.R175H 22

Copy number variations for Basal Cell Carcinoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 256908 9 98205264 98279247 Mutation PTCH Basal cell carcinoma

Expression for Basal Cell Carcinoma

Search GEO for disease gene expression data for Basal Cell Carcinoma.

Pathways for Basal Cell Carcinoma

Pathways related to Basal Cell Carcinoma according to KEGG:

36
# Name Kegg Source Accession
1 Basal cell carcinoma hsa05217

Pathways related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.87 CTNNB1 GLI1 GLI2 PTCH1 PTCH2 SMO
2 12.7 CTNNB1 GLI1 GLI2 PTCH1 PTCH2 SHH
3
Show member pathways
12.42 GLI1 GLI2 PTCH1 SHH SMO SUFU
4
Show member pathways
12.21 PTCH1 PTCH2 SHH SMO
5 12.14 CTNNB1 PTCH1 SHH SMO TP53
6 11.82 CTNNB1 CYLD GLI1 GLI2 PTCH1 PTCH2
7
Show member pathways
11.81 GLI1 GLI2 PTCH1 PTCH2 SHH SMO
8
Show member pathways
11.68 CTNNB1 GLI1 GLI2 MC1R PTCH1 PTCH2
9 11.36 GLI1 GLI2 PTCH1 SHH SMO
10
Show member pathways
11.17 GLI2 PTCH1 PTCH2 SHH SMO
11 11.13 GLI1 GLI2 SHH
12 10.4 PTCH1 SHH

GO Terms for Basal Cell Carcinoma

Cellular components related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cilium GO:0005929 9.55 GLI1 GLI2 PTCH1 SMO SUFU
2 ciliary base GO:0097546 9.13 GLI1 GLI2 SUFU
3 ciliary tip GO:0097542 9.02 CYLD GLI1 GLI2 SMO SUFU

Biological processes related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 75)
# Name GO ID Score Top Affiliating Genes
1 in utero embryonic development GO:0001701 9.99 CTNNB1 GLI2 PALB2 PTCH1 SMO
2 epidermis development GO:0008544 9.95 KRT15 KRT17 PTCH1 PTCH2
3 lung development GO:0030324 9.93 CTNNB1 GLI1 GLI2 SHH
4 kidney development GO:0001822 9.92 CTNNB1 GLI2 SHH
5 osteoblast differentiation GO:0001649 9.92 GLI1 GLI2 SMO
6 anterior/posterior pattern specification GO:0009952 9.91 GLI2 SHH SMO
7 canonical Wnt signaling pathway GO:0060070 9.91 CTNNB1 GLI1 SHH SMO
8 determination of left/right symmetry GO:0007368 9.9 SHH SMO SUFU
9 heart looping GO:0001947 9.89 SHH SMO SUFU
10 embryonic digit morphogenesis GO:0042733 9.88 CTNNB1 GLI2 SHH
11 vasculogenesis GO:0001570 9.88 CTNNB1 SHH SMO
12 branching involved in ureteric bud morphogenesis GO:0001658 9.87 CTNNB1 PTCH1 SHH
13 odontogenesis of dentin-containing tooth GO:0042475 9.84 CTNNB1 GLI2 SHH SMO
14 developmental growth GO:0048589 9.83 GLI2 SHH SMO
15 positive regulation of mesenchymal cell proliferation GO:0002053 9.83 CTNNB1 SHH SMO
16 pattern specification process GO:0007389 9.83 GLI2 PTCH1 SHH SMO
17 positive regulation of smoothened signaling pathway GO:0045880 9.82 GLI1 SHH SMO
18 skin development GO:0043588 9.81 CTNNB1 PTCH2 SHH SUFU
19 proximal/distal pattern formation GO:0009954 9.8 CTNNB1 GLI1 GLI2
20 hindbrain development GO:0030902 9.8 CTNNB1 GLI2 SHH
21 embryonic organ development GO:0048568 9.8 PALB2 PTCH1 SHH SMO
22 regulation of smoothened signaling pathway GO:0008589 9.79 GLI1 GLI2 PTCH1
23 negative regulation of smoothened signaling pathway GO:0045879 9.79 PTCH1 PTCH2 SUFU
24 positive regulation of neuroblast proliferation GO:0002052 9.77 CTNNB1 SHH SMO
25 smoothened signaling pathway GO:0007224 9.77 GLI1 GLI2 PTCH1 SHH SMO
26 spinal cord motor neuron differentiation GO:0021522 9.76 GLI2 PTCH1 SHH
27 negative regulation of chondrocyte differentiation GO:0032331 9.75 CTNNB1 GLI2
28 anatomical structure formation involved in morphogenesis GO:0048646 9.75 GLI2 SHH
29 intermediate filament organization GO:0045109 9.75 KRT17 SHH
30 osteoblast development GO:0002076 9.75 GLI2 SHH
31 cell fate specification GO:0001708 9.75 CTNNB1 SHH SMO
32 epithelial tube branching involved in lung morphogenesis GO:0060441 9.74 CTNNB1 SHH
33 anatomical structure development GO:0048856 9.74 GLI2 SHH
34 digestive tract morphogenesis GO:0048546 9.74 GLI1 SHH
35 mammary gland epithelial cell differentiation GO:0060644 9.74 PTCH1 SMO
36 cell fate determination GO:0001709 9.74 CTNNB1 PTCH1 PTCH2
37 thalamus development GO:0021794 9.73 SHH SMO
38 regulation of osteoblast differentiation GO:0045667 9.73 CTNNB1 GLI1
39 ectoderm development GO:0007398 9.73 CTNNB1 SHH
40 cellular response to cholesterol GO:0071397 9.73 PTCH1 SMO
41 hair follicle morphogenesis GO:0031069 9.73 CTNNB1 KRT17 SHH SMO
42 embryonic foregut morphogenesis GO:0048617 9.72 CTNNB1 SHH
43 positive regulation of T cell differentiation in thymus GO:0033089 9.72 GLI2 SHH
44 positive regulation of skeletal muscle tissue development GO:0048643 9.72 CTNNB1 SHH
45 somite development GO:0061053 9.72 PTCH1 SHH SMO
46 lung-associated mesenchyme development GO:0060484 9.71 CTNNB1 SHH
47 positive regulation of epidermal cell differentiation GO:0045606 9.71 PTCH1 PTCH2
48 renal system development GO:0072001 9.71 CTNNB1 PTCH1 SHH SMO
49 smoothened signaling pathway involved in dorsal/ventral neural tube patterning GO:0060831 9.7 GLI2 PTCH1
50 mammary gland duct morphogenesis GO:0060603 9.7 GLI2 PTCH1

Molecular functions related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription regulatory region DNA binding GO:0044212 9.62 CTNNB1 GLI1 GLI2 TP53
2 hedgehog family protein binding GO:0097108 9.26 PTCH1 PTCH2
3 smoothened binding GO:0005119 9.16 PTCH1 PTCH2
4 hedgehog receptor activity GO:0008158 8.96 PTCH1 PTCH2
5 patched binding GO:0005113 8.8 PTCH1 SHH SMO

Sources for Basal Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....